Ocular Therapeutix 10-Q: $94.8M Q3 Loss, $530.6M Cash, EyePoint Suit Settled
OCUL is trading near its 52-week low of $6 (3.3% above the low).
Summary
Ocular Therapeutix's Q3 10-Q shows a $94.8 million net loss on $12.9 million of revenue, offset by $530.6 million in cash that funds operations into 2028 and the planned Q4 2026 AXPAXLI NDA. It also discloses the October 30 EyePoint lawsuit settlement at no cost and a SOL-R protocol change moving the primary endpoint to Week 40.
Key Events · Earnings and Guidance · OCUL
-
Q3 Loss Widens to $94.8M
Net loss was $94.8 million, or $0.42 per share, versus $69.4 million, or $0.38 per share, a year earlier. Revenue fell to $12.9 million from $14.5 million as gross-to-net provisions rose to 57.7% of gross DEXTENZA sales.
-
R&D Jumps on Trial Enrollment
Research and development expense rose to $74.8 million from $52.4 million, driven by HELIOS-3 and SOL-X enrollment plus added headcount. Total operating expenses were $110.7 million versus $83.2 million.
-
Cash Funds Runway Into 2028
Cash and cash equivalents were $530.6 million at September 30, 2026, which the company says funds operating expenses, debt service and capex into 2028 while maintaining the $20.0 million minimum liquidity covenant on the Barings facility.
-
EyePoint Suit Settled at No Cost
The EyePoint defamation and tortious interference action was settled October 30, 2026 with a mutual release and no financial obligation beyond each party paying its own attorneys' fees; no accrual was recorded.
Analysis · OCUL · Life Sciences
The 10-Q confirms the $94.8 million third-quarter loss already reported in this morning's 8-K, but it carries details the headline missed. R&D jumped to $74.8 million from $52.4 million a year earlier as HELIOS-3 and SOL-X enrollment ramped, while revenue slipped to $12.9 million from $14.5 million on higher gross-to-net discounts. The $530.6 million cash balance funds operations into 2028, which covers the planned Q4 2026 AXPAXLI NDA filing without an immediate raise. Two other items matter: the EyePoint defamation suit was settled October 30 with no payment beyond each side's own legal fees, removing a legal overhang, and the SOL-R protocol was amended to move the primary endpoint to Week 40 with masking extended to Week 96 — a change the company says preserves trial integrity ahead of the interim safety analysis. The stock sits near its 52-week low of $6.00, so the market is already pricing skepticism about the NDA and launch; the cash position is what keeps the story alive until the filing.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OCUL was trading at $6.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $6.00 to $16.44. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.